Evaluation of Nonmodified Wireframe DNA Origami for Acute Toxicity and Biodistribution in Mice

ACS Appl Bio Mater. 2023 May 15;6(5):1960-1969. doi: 10.1021/acsabm.3c00155. Epub 2023 Apr 11.

Abstract

Wireframe DNA origami can be used to fabricate virus-like particles for a range of biomedical applications, including the delivery of nucleic acid therapeutics. However, the acute toxicity and biodistribution of these wireframe nucleic acid nanoparticles (NANPs) have not been previously characterized in animal models. In the present study, we observed no indications of toxicity in BALB/c mice following a therapeutically relevant dosage of nonmodified DNA-based NANPs via intravenous administration, based on liver and kidney histology, liver and kidney biochemistry, and body weight. Further, the immunotoxicity of these NANPs was minimal, as indicated by blood cell counts and type-I interferon and pro-inflammatory cytokines. In an SJL/J model of autoimmunity, we observed no indications of NANP-mediated DNA-specific antibody response or immune-mediated kidney pathology following the intraperitoneal administration of NANPs. Finally, biodistribution studies revealed that these NANPs accumulate in the liver within one hour, concomitant with substantial renal clearance. Our observations support the continued development of wireframe DNA-based NANPs as next-generation nucleic acid therapeutic delivery platforms.

Keywords: DNA origami; biodistribution; immunotoxicity; nanotechnology; therapeutic delivery; toxicity.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • DNA / chemistry
  • Mice
  • Nanoparticles* / chemistry
  • Nanoparticles* / toxicity
  • Nucleic Acids* / chemistry
  • Nucleic Acids* / therapeutic use
  • Tissue Distribution

Substances

  • DNA
  • Nucleic Acids